

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**(To be used for all correspondence
after initial filing)

Application Number	10/007,700
Filing Date	November 30, 2001
First Named Inventor	Tongtong Wang
Group Art Unit	1632
Examiner Name	
Attorney Docket No.	210121.455C17

RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (5 sheets) <input checked="" type="checkbox"/> Cited Reference (1) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
---	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey Hundley, Ph.D. 42,676	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	2/28/02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Monica Steinborn	
Signature		Date: 2/28/02



PATENT

RECEIVED

MAR 15 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tongtong Wang et al.
Application No. : 10/007,700
Filed : November 30, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF LUNG CANCER

TECH CENTER 1600/2900

Docket No. : 210121.455C17

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/897,778, filed June 28, 2001; which is a continuation-in-part of USAN 09/850,716, filed May 7, 2001; which is a continuation-in-part of USAN 09/735,705, filed December 12, 2000; which is a continuation-in-part of USAN 09/685,696, filed October 9, 2000; which is a continuation-in-part of USAN 09/662,786, filed September 15, 2000; which is a continuation-in-part of USAN 09/643,597, filed August 21, 2000; which is a continuation-in-part of USAN 09/630,940, filed August 2, 2000; which is a continuation-in-part of USAN 09/606,421, filed June 28, 2000; which is a continuation-in-part of USAN 09/542,615, filed April 4, 2000; which is a continuation-in-part of USAN 09/510,376, filed February 22, 2000; which is a continuation-in-part of USAN 09/480,884, filed January 10, 2000; which is a continuation-in-part of USAN 09/476,496, filed December 30, 1999; which is a continuation-in-part of USAN 09/466,396, filed December 17, 1999; which is a continuation-in-part of USAN 09/285,479, filed April 2, 1999; which is a continuation-in-part of USAN 09/221,107, filed December 22, 1998; which is a continuation-in-part of USAN 09/123,912, filed July 27, 1998; which is a continuation-in-part of USAN 09/040,802, filed March 18, 1998. The references listed on pages 1-4 of the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore,

are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request. However, the reference listed on page 5 of Forms PTO-1449 was not submitted to and/or cited by the Office and is submitted herewith.

As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Jeffrey Hundley, Ph.D.
Registration No. 42,676

JEH:mls

Enclosures:

Postcard

Form PTO-1449 (5 Sheets)

Copies of Cited References (1)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
(206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C17		APPLICATION NO. 10/007,700	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Tongtong Wang et al.			
				FILING DATE November 30, 2001		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	TRADEMARK OFFICE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,783,422	07/21/98	Suminami et al.	435	69.3	
	AB	5,705,159	01/06/98	Irie et al	424	185.1	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AC	WO 99/47674	09/23/99	WIPO			
	AD	WO 99/38973	08/05/99	WIPO			
	AE	WO 98/46788	10/22/98	WIPO			
	AF	WO 98/35985	08/20/98	WIPO			
	AG	WO 97/07244	02/27/97	WIPO			
	AH	WO 96/30389	10/03/96	WIPO			
	AI	WO 96/28473	09/19/96	WIPO			
	AJ	EP0695760A1	02/07/96	European Patent Office			
	AK	WO 96/02552	02/01/96	WIPO			
	AL	WO 95/21862	08/17/95	WIPO			
	AM	WO 94/06929	03/31/94	WIPO			
	AN	WO 91/18926	12/12/91	WIPO			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AO	Baldi et al., "Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer," <i>Clinical Cancer Research</i> 3(10):1691-1697, October 1997.					
	AP	Brass et al., "Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma," <i>Human Molecular Genetics</i> , 6(1): 33-39, 1997.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.455C17APPLICATION NO.
10/007,700

RECEIVED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tongtong Wang et al.

MAR 15 2002

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL & TRADEMARK OFFICE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION IF APPROPRIATE	
				YES	NO
BB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Database EMBL Nucleotide and Protein Sequence, Accession No. AI468638, March 17, 1999.
BD	Database EMBLest17 Accession No. AA340797:EST46165 Fetal kidney II Homo sapiens cDNA 3' end, April 18, 1997.
BE	Database EMBLest17 Accession No. W22264:Human retina cDNA Tsp-509I-cleaved sublibrary Homo sapiens cDNA not directional, May 9, 1996.
BF	Davidson et al., "Lung tumours immunoreactive for parathyroid hormone related peptide: analysis of serum calcium levels and tumour type," <i>Journal of Pathology</i> 178:398-401, January 1996.
BG	Finch et al., "Identification of a cloned sequence activated during multi-stage carcinogenesis in mouse skin," <i>Carcinogenesis</i> , 12(8):1519-1522, August 1991.
BH	Gerhold and Caskey, "It's the genes! EST access to human genome content," <i>BioEssays</i> 18(12):973-981, 1996.
BI	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
BJ	Henderson et al., "Identification of lung tumor antigens for cancer immunotherapy: immunological and molecular approaches," <i>Immunological Investigation</i> 29(2):87-91, May 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C17		APPLICATION NO. 10/007,700	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Tongtong Wang et al.		MAR 15 2002	
				FILING DATE November 30, 2001		GROUP ART UNIT 1632 TECH CENTER 1600/2900	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
CA							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
				YES NO			
CB							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
CC			Hogan et al., "The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene," <i>Cancer Research</i> 58(22):5144-5150, November 15, 1998.				
CD			Hu et al., "A small proline-rich protein, spr1: specific marker for squamous lung carcinoma," <i>Lung Cancer</i> 20:25-30, 1998.				
CE			Lelievre et al., "Structural properties of chimeric peptides containing a T-cell epitope linked to a fusion peptide and their importance for in vivo induction of cytotoxic T-cell responses," <i>European Journal of Biochemistry</i> 249(3):895-904, 1997.				
CF			Marshall and Hodgson, "DNA chips: an array of possibilities," <i>Nature Biotechnology</i> 16:27-31, January 1998.				
CG			Pastor et al., "Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis," <i>Eur. Respir J.</i> 10(3):603-609, March 1997.				
CH			Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, 1995.				
CI			Ramsay, G., "DNA chips: state-of-the art," <i>Nature Biotechnology</i> 16:40-44, January 1998.				
CJ			Ruppert et al., "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules," <i>Cell</i> 74:929-937, September 10, 1993.				
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C17		APPLICATION NO. 10/007,700		RECEIVED					
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Tongtong Wang et al.				MAR 15 2002					
				FILING DATE November 30, 2001		GROUP ART UNIT 1632		TECH CENTER 1600/2900					
U.S. PATENT DOCUMENTS													
* EXAMINER INITIAL		DOCUMENT NUMBER		DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
DA													
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER		DATE		COUNTRY				TRANSLATION			
										YES		NO	
DB													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
DC		Russell and Barton, "Structural features can be unconserved in proteins with similar folds," <i>J. Mol. Biol.</i> 244:332-350, 1994.											
DD		Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258:815-818, October 30, 1992.											
DE		Skeiky et al., "Cloning, expression and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis," <i>Infection and Immunity</i> 67(8):3998-4007, August 1999.											
DF		Theobald et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Acad. Sci. USA</i> 92:11993-11997, December 1995.											
DG		Visseren et al., "Identification of HLA-A *0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product," <i>International Journal of Cancer</i> 73(1):125-130, 1997.											
DH		Wang et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," <i>Oncogene</i> 19(12):1519-1528, March 16, 2000.											
DI		Wells and Peitsch, "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases," <i>Journal of Leukocyte Biology</i> 61:545-550, May 1997.											
DJ													
EXAMINER						DATE CONSIDERED							
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).													

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.455C17APPLICATION NO.
10/007,700

RECEIVED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tongtong Wang et al.

MAR 15 2002

FILING DATE

November 30, 2001

GROUP ART UNIT

1632

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
EB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EC	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157:4079-4086, 1996.
ED	
EE	
EF	
EG	
EH	
EI	
EJ	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).